Teva's new launches won't feel the sting of hefty cost cuts: CEO

Teva will be backing the launch of CGRP drug fremanezumab "100%," its new CEO said last week amid major cost-cutting announcements.

With Teva slated to cut 14,000 jobs and $3 billion in costs in the coming years, every area of the company will feel the impact of its restructuring plan. Well, almost.

“Basically the only thing we’re really protecting is the product flow,” new CEO Kåre Schultz recently told investors, adding that the drugmaker will be “making sure the sales efforts are not hampered.”

And that includes launches for a couple of key specialty products in Teva’s portfolio: newly approved Austedo, which bears indications in Huntington’s and tardive dyskinesia (TD), and closely watched CGRP migraine candidate fremanezumab.

3-Day Conference

6th Promotional Review Committee Compliance & Best Practices Conference

The leading U.S. event devoted to building the skills, speed and teamwork of your promotional review committee members will take place May 15–17, 2019 in Chicago. The conference is set to bring together more than 75 professionals to ensure your PRC is prepared to generate, collect and constructively act on expert comments for your entire drug and device portfolio.

RELATED: The top 15 generic drugmakers by 2016 revenueTeva

“We are backing fremanezumab 100%,” Schultz said. Among a tough field of competitors—including a Novartis-Amgen team-up—Teva is the only one whose product can be dosed once every three months, a factor “we think will be an advantage.”

“We have of course made sure we have the resources” to back the rollout and cue a “successful launch of Austedo,” he added.

Both drugs will need resources to compete against key rivals. Austedo, for one, went up against Neurocrine’s Ingrezza when it snagged its FDA green light for TD in August; Ingrezza was the first-ever product to win a TD indication when it did so in April.

RELATED: Teva takes on Neurocrine with TD nod for Austedo

And on the migraine side, Teva is vying with Novartis and Amgen—which filed an FDA application for their erenumab over the summer—as well as Eli Lilly, which submitted its own application earlier this month. Teva, for its part, saw the FDA accept its on fremanezumab application Monday; Alder BioPharmaceuticals trails the Israeli drugmaker with prospect eptinezumab.

Despite the list of heavyweight rivals, though, analysts expect Teva to become “one of the leaders in the CGRP space,” Credit Suisse’s Vamil Divan, M.D., wrote in a recent note to clients. “Fremanezumab stands out as one of the only assets of interest in the Teva branded pipeline.”

RELATED: Teva's stunning list of cuts targets 14K jobs, $3B in costs and plants around the globe

Meanwhile, though, the rest of Teva will feel the squeeze as the company embarks on a cost-cutting plan broader than industry watchers expected. “You basically look at everything and try to optimize everything in one go,” Schultz told investors about his approach to wringing out savings. The process also involves making sure the cost-cutting blueprints are “highly executable” and “borne out of specific targets for specific units.”

Suggested Articles

Sanofi is working on a succession plan for CEO Olivier Brandicourt, who'll hit mandatory retirement age in 2021.

Gilead CEO John Milligan racked up $26M in 2018 pay, on paper at least, while incoming chief Daniel O'Day is in line for a cool $30M this year.

Novo Nordisk has at least four more years to build up its newer diabetes drugs before they face Teva's versions of its $2.67B blockbuster Victoza.